Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 27

1.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.

Borisov S, Danila E, Maryandyshev A, Dalcolmo M, Miliauskas S, Kuksa L, Manga S, Skrahina A, Diktanas S, Codecasa LR, Aleksa A, Bruchfeld J, Koleva A, Piubello A, Udwadia ZF, Akkerman OW, Belilovski E, Bernal E, Boeree MJ, Loidi JC, Cai Q, Cebrian Gallardo JJ, Dara M, Davidavičienė E, Forsman LD, De Los Rios Jefe J, Denholm J, Drakšienė J, Duarte R, Elamin SE, Salinas NE, Ferrarese M, Filippov A, Garcia A, García-García JM, Gaudiesiute I, Gavazova B, Gayoso R, Rosso RG, Gruslys V, Gualano G, Hoefsloot W, Jonsson J, Khimova E, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Marchese V, Robles EM, Matteelli A, Mazza-Stalder J, Moschos C, Munoz-Torrico M, Hamdan HM, Nakčerienė B, Nicod L, Marcos MN, Palmero DJ, Palmieri F, Papavasileiou A, Payen MC, Pontarelli A, Quirós S, Rendon A, Saderi L, Šmite A, Solovic I, Souleymane MB, Tadolini M, van den Boom M, Vescovo M, Viggiani P, Yedilbayev A, Zablockis R, Zhurkin D, Zignol M, Visca D, Spanevello A, Caminero JA, Alffenaar JW, Tiberi S, Centis R, D'Ambrosio L, Pontali E, Sotgiu G, Migliori GB.

Eur Respir J. 2019 Oct 10. pii: 1901522. doi: 10.1183/13993003.01522-2019. [Epub ahead of print]

PMID:
31601711
2.

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study.

Akkerman O, Aleksa A, Alffenaar JW, Al-Marzouqi NH, Arias-Guillén M, Belilovski E, Bernal E, Boeree MJ, Borisov SE, Bruchfeld J, Cadiñanos Loidi J, Cai Q, Caminero JA, Cebrian Gallardo JJ, Centis R, Codecasa LR, D'Ambrosio L, Dalcolmo M, Danila E, Dara M, Davidavičienė E, Davies Forsman L, De Los Rios Jefe J, Denholm J, Duarte R, Elamin SE, Ferrarese M, Filippov A, Ganatra S, Garcia A, García-García JM, Gayoso R, Giraldo Montoya AM, Gomez Rosso RG, Gualano G, Hoefsloot W, Ilievska-Poposka B, Jonsson J, Khimova E, Kuksa L, Kunst H, Laniado-Laborín R, Li Y, Magis-Escurra C, Manfrin V, Manga S, Marchese V, Martínez Robles E, Maryandyshev A, Matteelli A, Migliori GB, Mullerpattan JB, Munoz-Torrico M, Mustafa Hamdan H, Nieto Marcos M, Noordin NM, Palmero DJ, Palmieri F, Payen MC, Piubello A, Pontali E, Pontarelli A, Quirós S, Rendon A, Skrahina A, Šmite A, Solovic I, Sotgiu G, Souleymane MB, Spanevello A, Stošić M, Tadolini M, Tiberi S, Udwadia ZF, van den Boom M, Vescovo M, Viggiani P, Visca D, Zhurkin D, Zignol M; members of the International Study Group on new anti-tuberculosis drugs and adverse events monitoring.

Int J Infect Dis. 2019 Jun;83:72-76. doi: 10.1016/j.ijid.2019.03.036. Epub 2019 Apr 3.

3.

Dolutegravir as a trigger for DRESS syndrome?

Martin C, Payen MC, De Wit S.

Int J STD AIDS. 2018 Sep;29(10):1036-1038. doi: 10.1177/0956462418764973. Epub 2018 Apr 5.

PMID:
29621952
4.

Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Centis R, Alffenaar JW, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702187. doi: 10.1183/13993003.02187-2017. Print 2018 Mar. No abstract available.

5.

In Reply: Synergy between amoxicillin and meropenem/clavulanate in drug-resistant tuberculosis.

Payen MC, De Wit S.

Int J Tuberc Lung Dis. 2018 Apr 1;22(4):465-466. doi: 10.5588/ijtld.18.0055-2. No abstract available.

PMID:
29562999
6.

Meropenem-clavulanate for drug-resistant tuberculosis: a follow-up of relapse-free cases.

Payen MC, Muylle I, Vandenberg O, Mathys V, Delforge M, Van den Wijngaert S, Clumeck N, De Wit S.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):34-39. doi: 10.5588/ijtld.17.0352.

PMID:
29297423
7.

Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond.

D'Ambrosio L, Bothamley G, Caminero Luna JA, Duarte R, Guglielmetti L, Muñoz Torrico M, Payen MC, Saavedra Herrera N, Salazar Lezama MA, Skrahina A, Tadolini M, Tiberi S, Veziris N, Migliori GB.

Pulmonology. 2018 Mar - Apr;24(2):132-141. doi: 10.1016/j.rppnen.2017.10.005. Epub 2017 Dec 8. Review.

8.

Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.

Borisov SE, Dheda K, Enwerem M, Romero Leyet R, D'Ambrosio L, Centis R, Sotgiu G, Tiberi S, Alffenaar JW, Maryandyshev A, Belilovski E, Ganatra S, Skrahina A, Akkerman O, Aleksa A, Amale R, Artsukevich J, Bruchfeld J, Caminero JA, Carpena Martinez I, Codecasa L, Dalcolmo M, Denholm J, Douglas P, Duarte R, Esmail A, Fadul M, Filippov A, Davies Forsman L, Gaga M, Garcia-Fuertes JA, García-García JM, Gualano G, Jonsson J, Kunst H, Lau JS, Lazaro Mastrapa B, Teran Troya JL, Manga S, Manika K, González Montaner P, Mullerpattan J, Oelofse S, Ortelli M, Palmero DJ, Palmieri F, Papalia A, Papavasileiou A, Payen MC, Pontali E, Robalo Cordeiro C, Saderi L, Sadutshang TD, Sanukevich T, Solodovnikova V, Spanevello A, Topgyal S, Toscanini F, Tramontana AR, Udwadia ZF, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2017 May 21;49(5). pii: 1700387. doi: 10.1183/13993003.00387-2017. Print 2017 May.

9.

Isolation unit for multidrug-resistant tuberculosis patients in a low endemic country, a step towards the World Health Organization End TB Strategy.

Payen MC, VAN Vooren JP, Vandenberg O, Clumeck N, DE Wit S.

Epidemiol Infect. 2017 May;145(7):1368-1373. doi: 10.1017/S0950268817000267. Epub 2017 Feb 16.

PMID:
28202091
10.

Faster for less: the new "shorter" regimen for multidrug-resistant tuberculosis.

Sotgiu G, Tiberi S, D'Ambrosio L, Centis R, Alffenaar JW, Caminero JA, Abdo Arbex M, Alarcon Guizado V, Aleksa A, Dore S, Gaga M, Gualano G, Kunst H, Payen MC, Roby Arias AJ, Skrahina A, Solovic I, Sulis G, Tadolini M, Zumla A, Migliori GB; International Carbapenem Study Group.

Eur Respir J. 2016 Nov;48(5):1503-1507. doi: 10.1183/13993003.01249-2016. Epub 2016 Sep 1. No abstract available.

11.

Is systematic screening and treatment for latent tuberculosis infection in HIV patients useful in a low endemic setting?

Maniewski U, Payen MC, Delforge M, De Wit S.

Acta Clin Belg. 2017 Aug;72(4):238-241. doi: 10.1080/17843286.2016.1237696. Epub 2016 Sep 30.

PMID:
27686180
12.

Immune Activation by Mycobacterium tuberculosis in HIV-Infected and -Uninfected Subjects.

Wyndham-Thomas C, Corbière V, Selis E, Payen MC, Goffard JC, Van Vooren JP, Mascart F, Dirix V.

J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):103-111.

PMID:
27532475
13.

Comparison of effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Abdo Arbex M, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Auchynka V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Jun;47(6):1758-66. doi: 10.1183/13993003.00214-2016. Epub 2016 Apr 13.

14.

Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.

Tiberi S, Payen MC, Sotgiu G, D'Ambrosio L, Alarcon Guizado V, Alffenaar JW, Abdo Arbex M, Caminero JA, Centis R, De Lorenzo S, Gaga M, Gualano G, Roby Arias AJ, Scardigli A, Skrahina A, Solovic I, Sulis G, Tadolini M, Akkerman OW, Alarcon Arrascue E, Aleska A, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Eur Respir J. 2016 Apr;47(4):1235-43. doi: 10.1183/13993003.02146-2015. Epub 2016 Mar 10.

15.

Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.

Tiberi S, Sotgiu G, D'Ambrosio L, Centis R, Arbex MA, Alarcon Arrascue E, Alffenaar JW, Caminero JA, Gaga M, Gualano G, Skrahina A, Solovic I, Sulis G, Tadolini M, Alarcon Guizado V, De Lorenzo S, Roby Arias AJ, Scardigli A, Akkerman OW, Aleksa A, Artsukevich J, Avchinko V, Bonini EH, Chong Marín FA, Collahuazo López L, de Vries G, Dore S, Kunst H, Matteelli A, Moschos C, Palmieri F, Papavasileiou A, Payen MC, Piana A, Spanevello A, Vargas Vasquez D, Viggiani P, White V, Zumla A, Migliori GB.

Clin Infect Dis. 2016 May 1;62(9):1188-90. doi: 10.1093/cid/ciw088. Epub 2016 Feb 16. No abstract available.

PMID:
26908794
16.

Acute myocardial infarction following thalidomide treatment for AIDS-related ulcers.

Dauby N, Coussement J, Karakike E, Ungureanu C, De Wit S, Payen MC.

AIDS. 2015 Jun 1;29(9):1119-20. doi: 10.1097/QAD.0000000000000656. No abstract available.

PMID:
26125145
17.

Epidemiology of MDR-TB in a Belgian infectious diseases unit: a 15 years review.

van Heurck R, Payen MC, De Wit S, Clumeck N.

Acta Clin Belg. 2013 Sep-Oct;68(5):321-4.

PMID:
24579238
18.

Meningitis and splenic infarction due to disseminated Mycobacterium genavense infection in an HIV patient. Case report and review of the literature.

Kyrilli A, Payen MC, Antoine-Moussiaux T, Dewit S, Clumeck N.

Acta Clin Belg. 2013 May-Jun;68(3):220-2. Review.

PMID:
24156225
19.

Clinical use of the meropenem-clavulanate combination for extensively drug-resistant tuberculosis.

Payen MC, De Wit S, Martin C, Sergysels R, Muylle I, Van Laethem Y, Clumeck N.

Int J Tuberc Lung Dis. 2012 Apr;16(4):558-60. doi: 10.5588/ijtld.11.0414.

PMID:
22325421
20.

Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis.

Dauby N, Muylle I, Mouchet F, Sergysels R, Payen MC.

Pediatr Infect Dis J. 2011 Sep;30(9):812-3. doi: 10.1097/INF.0b013e3182154b05.

PMID:
21378593
21.

Amikacin-induced hypomagnesaemic tetany complicating multidrug-resistant tuberculosis treatment.

Dauby N, Payen MC.

Int J Tuberc Lung Dis. 2010 May;14(5):657-8. No abstract available.

PMID:
20392363
22.

[Lipids and AIDS].

Ducobu J, Payen MC.

Rev Med Brux. 2000 Feb;21(1):11-7. French.

PMID:
10748683
23.
24.

[Manifestations, diagnosis and treatment of non-tuberculous mycobacterial infections in patients with HIV infection].

Payen MC, De Wit S, Clumeck N.

Rev Mal Respir. 1997 Dec;14 Suppl 5:S142-51. Review. French.

PMID:
9496599
25.
26.

[HIV and vaccines].

Payen MC.

Acta Urol Belg. 1993 Jan-Jun;61(1-2):607-14. Review. French. No abstract available.

PMID:
8517278
27.

[Diagnostic criteria in acute necrotizing pancreatitis].

Wettendorff P, Payen MC.

Acta Gastroenterol Belg. 1988 Jan-Feb;51(1):13-22. Review. French. No abstract available.

PMID:
3055786

Supplemental Content

Loading ...
Support Center